Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Monte Rosa (GLUE) shares rise as it teams with Johnson & Johnson to test MRT-2359 + ERLEADA in mCRPC AR mutations in a Phase ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in ...

A new study explores how decreased testosterone and high fructose intake may interact to influence the development of fatty ...

A mega-study of 117 mammal species reveals that limiting reproduction increases life expectancy by up to 10 percent.

In a major departure from the existing law, The Transgender Persons (Protection of Rights) Amendment Bill 2026 introduced in ...

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

The combination of low testosterone and high fructose intake revealed changes in gut microbiota and increased fat on the liver.

The median OS was 28 months with abiraterone-prednisone, 37 months with olaparib alone, and 68 months with abiraterone-prednisone-olaparib. In patients with metastatic castration-resistant prostate ...

Low testosterone in itself can cause a variety of health problems, but the addition of a poor diet can exacerbate certain ...

Osaka Metropolitan University researchers revealed that reduced levels of testosterone combined with fructose intake led to a ...